Liquid Biopsy Evaluation and Repository Development at Princess Margaret

Plain-language summary

This study (LIBERATE) aims to evaluate liquid biopsy in cancer patients and to build a sample biobank for future research. People aged 18 and over with a diagnosed solid tumor or blood cancer, or who are at high risk of cancer, may take part. It is a study without an assigned phase and is currently still enrolling participants.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Recruiting

Sponsor

University Health Network, Toronto

Start date

8/3/2017

Estimated completion

7/6/2026

Countries

Canada

Related genes

Locations

• Toronto, Canada

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

1. Patients with either histological confirmation of a solid tumor or hematological malignancy, OR patients identified as high-risk for cancer (based on identified aberration in cancer predisposition gene or on hormonal and/or family history without known aberration).
2. Patient must be ≥ 18 years old.
3. All patients must have signed and dated an informed consent form for this LIBERATE study.
4. If patients are being co-consented for a separate primary research study listed in Appendix I, they must fulfill the eligibility criteria for that separate primary research study. If there is a discrepancy in the eligibility criteria between protocols, the separate primary research study's criteria take precedence.

Exclusion Criteria:

None